Compare Garmin Ltd. (GRMN) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Garmin Ltd. vs Johnson & Johnson — how do they compare? Garmin Ltd. trades at $268.14 (market cap $51.77B), while Johnson & Johnson trades at $260.02 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 11.9× Garmin Ltd.'s market cap, and Johnson & Johnson pays the higher dividend (2.09%). Which is the better fit depends on your goals — on Pluang, investors hold Garmin Ltd. for 83 Days and Johnson & Johnson for 129 Days on average.
| GRMN | JNJ | |
|---|---|---|
Market Cap | $51.77B | $618.09B |
Volume | 961,398 | 6,050,983 |
Sector | Technology | Health |
52-Week High | $313.16 | $278.43 |
52-Week Low | $187.10 | $186.00 |
Typical Hold Time | 83 Days | 129 Days |
Enterprise Value | $49.28B | $646.37B |
Dividend Yield | 1.56% | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Garmin (GRMN) trades at $268.51, down 2.77% today, amid a bearish technical signal. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue and net income show steady growth, reaching $7.25B and $1.66B in 2025, respectively, supported by strong profitability margins. Recent news highlights product innovations and industry awards, reinforcing its market position.
The outlook remains positive given earnings momentum and a consensus price target of $320.25, implying significant upside. However, high valuation ratios and bearish technical indicators pose near-term risks. Investors should weigh strong fundamentals against potential volatility and competitive pressures in the consumer electronics space.
Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Garmin Ltd.
Garmin produces GPS-enabled hardware and software for five verticals: fitness, outdoors, auto, aviation, and marine. The company relies on licensing mapping data to enable its hardware specialized for often niche activities like scuba diving or sailing. Garmin operates in 100 countries and sells its products via distributors as well as relationships with original equipment manufacturers.
Read more on GRMN →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
